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OBJECTIVE—Ciliary neurotrophic factor (CNTF) reverses
muscle insulin resistance by increasing fatty acid oxidation
through gp130-LIF receptor signaling to the AMP-activated pro-
tein kinase (AMPK). CNTF also increases Akt signaling in
neurons and adipocytes. Because both Akt and AMPK regulate
glucose uptake, we investigated muscle glucose uptake in re-
sponse to CNTF signaling in lean and obese mice.
RESEARCH DESIGN AND METHODS—Mice were injected
intraperitoneally with saline or CNTF, and blood glucose was
monitored. The effects of CNTF on skeletal muscle glucose
uptake and AMPK/Akt signaling were investigated in incubated
soleus and extensor digitorum longus (EDL) muscles from
muscle-speciﬁc AMPK2 kinase-dead, gp130
STAT, and lean and
obese ob/ob and high-fat–fed mice. The effect of C2-ceramide on
glucose uptake and gp130 signaling was also examined.
RESULTS—CNTF reduced blood glucose and increased glucose
uptake in isolated muscles in a time- and dose-dependent manner
with maximal effects after 30 min with 100 ng/ml. CNTF in-
creased Akt-S473 phosphorylation in soleus and EDL; however,
AMPK-T172 phosphorylation was only increased in soleus. Incu-
bation of muscles from AMPK kinase dead (KD) and wild-type
littermates with the PI3-kinase inhibitor LY-294002 demonstrated
that PI3-kinase, but not AMPK, was essential for CNTF-stimu-
lated glucose uptake. CNTF-stimulated glucose uptake and Akt
phosphorylation were substantially reduced in obesity (high-fat
diet and ob/ob) despite normal induction of gp130/AMPK signal-
ing—effects also observed when treating myotubes with C2-
ceramide.
CONCLUSIONS—CNTF acutely increases muscle glucose up-
take by a mechanism involving the PI3-kinase/Akt pathway that
does not require AMPK. CNTF-stimulated glucose uptake is
impaired in obesity-induced insulin resistance and by ceramide.
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S
keletal muscle glucose uptake is regulated by
both intrinsic and circulating factors involving
the phosphatidylinositol (PI3)-kinase/Akt and the
AMP-activated protein kinase (AMPK) signaling
pathways (1). The regulation of muscle glucose uptake by
both pathways converges on AS160 (TBC1D4) and TBC1D1
where phosphorylation inhibits the negative regulation of
GLUT4 vesicle translocation (2–4) to the plasma mem-
brane (5,6). In insulin-resistant skeletal muscle, reduced
insulin receptor substrate (IRS) and Akt activation results
in reduced skeletal muscle glucose uptake (7,8). In con-
trast, activation of AMPK by endogenous circulating fac-
tors, including adiponectin (9,10) and interleuken (IL)-6
(11–13), and by pharmacological agents such as 5-amino-
imidazole-4-carboxamide riboside (AICAR) (14,15) in-
creases muscle glucose uptake, and this response is
maintained in muscle from diabetic rodents and humans
(16–19).
We have recently shown that the ciliary neurotrophic
factor (CNTF), a member of the IL-6 family, also acti-
vates muscle AMPK and increases lipid oxidation (20).
CNTF elicits intracellular signaling pathways by ligand
binding to the CNTF receptor  (CNTFR), which
initiates heterodimerization and activation of gp130 and
leukemia inhibitory factor (LIF) receptor, the two trans-
membrane  subunits of the receptor complex (21). This
differs from the initial step in IL-6 signaling, which
induces homodimerization of two gp130 subunits and
does not involve LIF (22). Formation of the CNTFR-
gp130-LIF complex leads to association with isoforms of
janus kinases, and these subsequently phosphorylate
speciﬁc tyrosine residues on the intracellular domains,
creating docking sites for Src homology–containing
tyrosine phosphatase 2 (SH2)-containing proteins
(23,24). Phosphorylation of Y757 of the intracellular
domain of the  subunit leads to activation of the
PI3-kinase/Akt pathway. Activation of the PI3-kinase by
gp130-LIF relies on association of the p85 subunit with
the regulatory SH2 domain–containing adapter mole-
cule GAB1 coordinated by SHP2 (25), and the assem-
bling of the complex does not involve IRS-1 (26).
Phosphorylation of four more distal tyrosine residues
leads to activation of the signal transducer and activator
of transcription (STAT) 1 and 3 (23). This distal domain
is responsible for AMPK activation by an adenosine
nucleotide-dependent mechanism (27). Because both
AMPK and PI3 kinase/Akt signaling are enhanced by
activation of the gp130-LIF receptor, our ﬁrst aim was to
test whether CNTF increases glucose uptake in skeletal
muscle and the signaling pathway(s) invoked.
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obesity is multifactorial and appears to be related to at
least two major events: chronic low-grade inﬂammation
and intramyocellular lipid accumulation (7,28). Both
events activate inhibitory IRS-1 kinases such as IB ki-
nase- (29,30), c-jun terminal amino kinase (28), and
protein kinase C  (31), which impair insulin signaling by
inhibiting IRS-1 association with PI3-kinase subunits. Al-
though this is believed to be a signiﬁcant element in
muscle insulin resistance, the sphingolipid ceramide also
impairs insulin signaling by promoting protein phospha-
tase 2A–dependent Akt dephosphorylation, thereby inhib-
iting Akt activation (32,33). Thus, because gp130-LIF
signaling to glucose uptake would be expected to be
independent of IRS-1, our second aim was to determine
whether gp130-LIF signaling toward glucose uptake is
maintained in mice with obesity-induced insulin resis-
tance. Analysis of the molecular pathways of CNTF signal-
ing to glucose uptake may provide important insights into
the function of gp130-LIF signaling and reveal the potential
of a novel therapeutic target for type 2 diabetes.
RESEARCH DESIGN AND METHODS
Animals. C57Bl6/J, ob/ob, AMPK2 kinase-dead (KD) and gp130
STAT mice
aged 8 to 18 weeks with corresponding littermate controls were used in
experiments. Transgenic mice overexpressing a KD form of the AMPK2
protein under control of the muscle creatine kinase promoter have been
described previously (34). Brieﬂy, the KD mutation was generated by
Lys45Arg mutagenesis to encode a KD 2 protein that displaces all detectable
endogenous 2 and 50–70% of endogenous 1 protein from  heterotrimer
complexes (34,35). The knockin mutant gp130
STAT mice express a COOH-
terminal truncation mutation of gp130 that prevents activation of STAT1/3 as
described previously (36). This mutation has a deletion of the distal intracel-
lular domain responsible for AMPK and STAT activation. All mice were kept
at a 12:12 h light:dark cycle at 20–21°C and provided ad libitum access to food
and water. Mice were maintained on a standard rodent chow diet/low-fat diet
(5% calories fat; Harlan Teklad) except in high-fat diet (HFD) experiments, in
which the diet was composed of 45% calories from fat (SF04–027; Specialty
Feeds). All procedures were approved by the St. Vincent’s Hospital Animal
Ethics Committee.
CNTF tolerance test. C57Bl6/J mice were fasted for 6 h before being
injected with either saline or 0.3 mg/kg CNTF, a concentration of CNTF that
activates AMPK and induces weight loss without eliciting an inﬂammatory
response (20). Blood glucose was monitored over 150 min.
Muscle incubations. Soleus (oxidative and glycolytic ﬁbers) and extensor
digitorum longus (EDL; primarily glycolytic ﬁbers) muscles were dissected
from anesthetized mice (6 mg of pentobarbital per 100 g
1 body weight) and
transferred to incubation ﬂasks containing 2 ml of essential buffer (Krebs-
Henseleit buffer, pH 7.4, with 2 mmol/l pyruvate, 8 mmol/l mannitol, and 0.1%
BSA), gassed with 95% O2  5% CO2, and maintained at 30°C as previously
described (15). For all experiments, muscles were preincubated for 15 min in
this buffer before it was replaced with buffer containing AICAR (2 mmol/l for
40 min; Toronto Research Chemicals Inc, Ontario, Canada), CNTF (at con-
centrations and durations indicated above, Axokine; Regeneron Pharmaceu-
ticals Inc, New York), or insulin (30 nmol/l [additivity study] or 2.8 nmol/l
[HFD study] for 40 min, Actrapid; Novo Nordisk, Bagsvaerd, Denmark). In
separate experiments, muscles were incubated in LY-294002 hydrochloride
(37) (60 nmol/l for 30 min; Sigma-Aldrich Corp, St. Louis, MO) before
treatment with CNTF or insulin as described.
2-deoxy-D-glucose (2DG) uptake was measured over 10 min by replacing
existing incubation buffer with the buffer described above but with the
addition of 0.5 	Ci/ml
12-[2,6-
3H]-deoxy-D-glucose, 1 mmol/l 2-deoxy-D-glu-
cose, and 0.2 	Ci [1-
14C]-mannitol/ml. After preparing muscles as described
below, radioactivity was measured in muscle lysates by liquid scintillation
counting (Tri-Carb 2000; Packard Instrument Co).
Muscle lysate preparation. Muscles were homogenized in ice-cold buffer
(50 mmol/l Hepes, pH 7.4, 150 mmol/l NaCl, 10 mmol/l NaF, 1 mmol/l sodium
pyrophosphate, 0.5 mmol/l EDTA, 250 mmol/l sucrose, 1 mmol/l dithiothreitol,
1% TritonX-100, 1 mmol/l Na3VO4, and one Roche protease inhibitor tablet per
50 ml buffer) using an electrical homogenizer. Lysates were prepared as
previously described (38) and stored at 80°C until analysis. Protein content
in lysates was measured by the bicinchoninic acid method (Pierce).
Immunoblotting. Expression or phosphorylation of investigated proteins
was determined in muscle lysates by SDS-PAGE and immunoblotting using
the following primary antibodies: pan-AMPK, phospho-AMPK T172, and
phospho–acetyl CoA carboxylase (ACC) S222 (as previously described [39]),
STAT3, phospho-STAT3 Y705, Akt, and phospho-Akt S473 (Cell Signaling
Technology Inc). Secondary antibodies were horseradish-conjugated protein
G (Bio-Rad Laboratories, Richmond, CA). Bands were visualized using an
enhanced chemoluminescence system and quantiﬁed using ImageQuant TL 05
software (Amersham Biosciences, U.K.). Values obtained using phospho-
speciﬁc antibodies are expressed as the ratio to the total content of the
protein measured after stripping the membrane and reprobing.
AMPK activity. AMPK1 and -2 activities were measured from 100 	go f
muscle lysate protein using rabbit polyclonal AMPK antibodies for immuno-
precipitation as previously described (40).
Muscle lipids. Lipids were extracted from freeze-dried powdered gastrocne-
mius muscle tissues using chloroform:methanol:PBS (1:2:0.8) and 0.2% SDS.
Triacylglycerol were saponiﬁed in an ethanol-KOH solution at 60°C, and
glycerol content was measured ﬂuorometrically. Diacylglycerols and cer-
amides were extracted and quantiﬁed according to the methods of Preiss et al.
(41).
Muscle cell studies. Muscle cells were differentiated and serum starved
overnight. The next morning, 20 nmol/l C2-dihydroceramide (Toronto Re-
search Chemicals Inc, Ontario, Canada) was added for 6 h before cells were
treated for 20 min with either CNTF (10 ng/ml) or insulin (10 nmol/l) before
collecting protein lysates or measuring 2DG uptake as previously described
(20). C2C12 cell were used for signaling experiments and L6 muscle cells for
2DG uptake because of the limited capacity of C2C12 to increase glucose
uptake in response to stimuli.
Data are expressed as means 
 SE. Statistical evaluations were performed
by either Student’s t test or two-way ANOVA using the Student-Newman-Keuls
method as a post hoc test when appropriate. Differences between groups were
considered statistically signiﬁcant if P  0.05.
RESULTS
In vivo effects of ciliary neurotrophic factor on blood
glucose. Injection of mice with CNTF was associated with
a reduction in blood glucose after 40 min compared with
saline-injected controls. Blood glucose remained reduced
in the CNTF group throughout the remainder of the test
(Fig. 1A). The AUC was 20% lower in CNTF-treated mice
than in saline-injected controls (Fig. 1B).
Muscle glucose uptake: ciliary neurotrophic factor
dose response. The effects of CNTF to reduce blood
glucose in vivo may have been mediated by the suppres-
sion of hepatic glucose production or increased glucose
uptake into adipose tissue and skeletal muscle. Therefore,
to directly test the effects of CNTF on skeletal muscle
glucose uptake, we incubated isolated muscles with CNTF
at concentrations ranging from 2 to 500 ng/ml. CNTF
increased muscle glucose uptake over 30 min in a dose-
dependent manner with a signiﬁcant increase at 2 ng/ml in
both soleus and EDL muscles (Fig. 2A–B). Glucose uptake
was elevated with increasing CNTF concentrations up to
100 ng/ml with no further increases observed at 500 ng/ml
(Fig. 2A and B), consistent with dose-dependent effects on
fatty acid oxidation observed previously (20). We next
investigated if the effect of CNTF on glucose uptake was
additive to the effects of insulin and AICAR. In soleus,
CNTF, insulin, and AICAR independently increased glu-
cose uptake to a similar degree, and combining AICAR and
insulin with CNTF had an additive effect (Fig. 2C). In EDL,
insulin and AICAR increased glucose uptake more strongly
than CNTF and no further increase was observed when
combining these treatments with CNTF (Fig. 2D).
Time course of CNTF-stimulated muscle glucose up-
take and signaling. CNTF increased glucose uptake in
soleus and EDL after 30 min—an effect that diminished
thereafter in both muscle types (Fig. 3A). CNTF has been
reported to increase the activity/phosphorylation of AMPK
in muscle (20) and Akt in neurons (42), and because both
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their activating phosphorylation. CNTF increased Akt
S473-P nearly 200% in soleus and 450% in EDL muscle, and
these effects diminished after 90 min (Fig. 3B). AMPK
T172-P was increased 90% in the soleus with CNTF after 30
min, and this was maintained for 60 min (Fig. 3C). Al-
though CNTF induced an apparent rise in ACC S218-P in
soleus, this did not achieve statistical signiﬁcance (P 
0.09) (Fig. 3D). CNTF had no detectable effect on AMPK-
or ACC-P in EDL (Fig. 3C–D), which is consistent with
previous observations in glycolytic muscle (20).
Effects of PI3-kinase inhibition and ablated AMPK
activity on CNTF actions. We next examined the rela-
tive importance of AMPK and PI3K/Akt signaling for
CNTF-mediated glucose uptake. Muscles from wild-type
and AMPK KD mice were preincubated with or without the
PI3-kinase inhibitor, LY-294002, followed by stimulation
with CNTF. Glucose uptake was increased to a similar
degree with CNTF in wild-type and AMPK KD muscles,
indicating that this response was AMPK independent.
CNTF-stimulated glucose uptake was abolished by LY-
294002 in both muscle types irrespective of mouse geno-
type (Fig. 4A), which is consistent with PI3-kinase/Akt
signaling being essential for this response.
We next measured -isoform–speciﬁc AMPK activity to
verify that CNTF had activated AMPK signaling in wild-
type mice and that the activation was impaired in AMPK
KD muscles (Fig. 4B). As anticipated, overexpression of
the AMPK KD construct lowered basal AMPK activity of
both -AMPK isoforms in both muscle types, with the most
pronounced effect on 2-AMPK activity (34). In wild-type
soleus, CNTF increased 1-AMPK activity by 180% and
2-AMPK activity by 35%, whereas CNTF had no effect on
either AMPK isoform in AMPK KD muscles (Fig. 4B).
CNTF did not increase AMPK activity in the EDL (Fig. 4B),
which is consistent with CNTF not increasing AMPK
phosphorylation in the EDL muscle (Fig. 3C).
Lastly, to establish whether inhibition of PI3-kinase or
AMPK signaling altered proximal CNTF signaling through
the gp130-LIF receptor complex, we examined STAT3
Y705-P in the EDL muscle of wild-type and AMPK KD mice
in the absence or presence of LY-294002. Incubation with
CNTF increased STAT3 Y705-P by 140% in wild-type
muscle, and importantly, the increase was unaffected in
AMPK-KD muscles and unaffected by coincubation with
LY-294002 (Fig. 4C). We also veriﬁed that increases in
Akt-P with CNTF were not affected by overexpression of
the AMPK KD construct and that LY 294002 inhibited Akt
activation (Fig. 4D). Similar ﬁndings were observed in the
soleus muscle (data not shown).
CNTF-stimulated glucose uptake in gp130
STAT
muscles. Signaling from the gp130-LIF receptor complex
activates two distinct intracellular signaling pathways. The
ﬁrst depends on phosphorylation of four tyrosine residues
(Y765, Y812, Y904, and Y914) on the distal cytoplasmic tail
of gp130, which is required and sufﬁcient for activating
STAT1/3 (23) and AMPK (20). The second arm requires
phosphorylation of the more proximal Y757 residue in
gp130, which induces ERK and PI3-kinase/Akt signaling
(23). We incubated muscles from gp130
STAT mice, which
have a deletion of the cytosolic distal portion of the gp130
receptor required for induction of STAT1/3 and AMPK
signaling but retain the Y757 residue that is required for
activation of Erk and PI3-kinase/Akt signaling. Incubation
with CNTF increased glucose uptake in soleus and EDL of
wild-type mice, and this increase was maintained in
gp130
 STAT knockin mutant mice (Fig. 5A). CNTF in-
creased Akt S473-P in both genotypes, whereas STAT3
Y705-P was increased in wild-type but not in gp130
STAT
muscles as expected (Fig. 5B). Thus, CNTF increased
glucose uptake normally despite impaired gp130 signaling
and activation of AMPK.
Effects of obesity on CNTF-stimulated muscle glu-
cose uptake and signaling. It is well established that
obesity is associated with impaired insulin sensitivity in
skeletal muscle, and impaired activation of IRS-1 has been
attributed a primary role (28,43). Because CNTF stimu-
lates glucose uptake downstream of IRS-1, we tested
whether CNTF-stimulated glucose uptake is maintained in
muscles from mice fed a HFD for 12 weeks and obese mice
deﬁcient in leptin (ob/ob). As dictated by design, the
high-fat feeding increased body weight by 
20% (chow,
28.4 
 0.5 g; HFD, 34.0 
 0.7 g), fasting insulin levels
(836 
 76 pg/ml to 1,670 
 377 pg/ml), and the AUC during
a GTT (chow, 539 
 23; HFD, 870 
 94). Similarly, ob/ob
mice had dramatically increased body mass (wild-type,
FIG. 1. In vivo effects of CNTF on blood glucose. A: CNTF tolerance test. Change in blood glucose over time. B: AUC. Animals were injected with
either CNTF (0.3 mg/kg) or saline, and changes in tail blood glucose were monitored over 150 min. n  10. Data are means  SEM. *Signiﬁcantly
different from saline.
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 0.7 g; ob/ob, 57.3 
 2.8 g) and AUC during a GTT
(WT, 574 
 26; ob/ob, 1,347 
 98). CNTF increased glucose
uptake by 80 to 100% in the soleus and EDL in chow-fed
mice, whereas CNTF-stimulated glucose uptake was com-
pletely blunted in the soleus and reduced by 
50% in EDL
of mice fed a HFD (Fig. 6A). Similarly, CNTF increased
muscle glucose uptake in both muscle types of lean
littermates of ob/ob mice; however, this increase was
abolished in muscles from ob/ob mice (Fig. 6B).
We then examined the mechanism by which obesity
inhibited CNTF-stimulated glucose uptake. CNTF in-
creased STAT3 Y705-P in skeletal muscle of chow- and
HFD-fed animals (Fig. 6C), indicating no impairment of
CNTF action at the receptor level. CNTF-induced Akt
S473-P was increased by 4- and 19-fold in soleus and EDL
of chow-fed mice, respectively, and this increase was
markedly impaired with obesity in both muscle types (Fig.
6D). In contrast, AMPK T172-P in soleus was also unaf-
fected by diet (Fig. 6E).
Muscle lipids and CNTF signaling. High-fat feeding
increased muscle contents of triacylglycerol, diacylglyc-
erol, and ceramide by 
100%, 
50%, and 
50%, respec-
tively, compared with chow-fed controls (Fig. 7A).
Because ceramides have been shown to directly inhibit
insulin-stimulated Akt phosphorylation (33), we tested
whether exposure of cultured myotubes to a short-chain
ceramide analog also impaired CNTF-stimulated glucose
uptake and Akt phosphorylation. Consistent with our
ﬁndings in obese skeletal muscle, myotubes treated with
C2-ceramide had impaired CNTF-stimulated glucose up-
take (Fig. 7B). Reductions in glucose uptake were not the
result of inhibition of the gp130-LIF receptor complex
because CNTF increased STAT3-P by 
350% in both
vehicle and C2-ceramide–treated cells (Fig. 7C). However,
C2-ceramide reduced basal and CNTF-stimulated Akt
S473-P (Fig. 7D). AMPK T172-P was increased (P  0.05)
by 60% with CNTF, and this increase was unaffected by
C2-ceramide treatment (Fig. 7E).
DISCUSSION
CNTF can regulate metabolic and growth signaling path-
ways in several tissue types. The present study shows that
CNTF regulates glucose uptake and delineates the proxi-
mal signaling events mediating this response. We show
that acute exposure of CNTF reduces blood glucose in
FIG. 2. Dose-dependent effect of CNTF on 2-deoxyglucose (2DG) glucose uptake and additive effects of CNTF on AICAR and insulin stimulated
glucose uptake. A and B: Muscles were either incubated with vehicle (BAS) condition or stimulated with CNTF at indicated concentrations for
30 min; n  8. *Signiﬁcantly different from basal condition (P < 0.05). C and D: Muscles were incubated with CNTF (100 ng/ml), insulin (30
nmol/l), AICAR (2 mmol/l), or indicated combinations, and changes in 2DG uptake are expressed as fold increases over basal. n  7–8. Data are
means  SEM. *Signiﬁcantly different from CNTF in the same muscle type.
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FIG. 3. Time-dependent effect of CNTF on 2-deoxyglucose (2DG) uptake, Akt S473, AMPK T172, and ACC S218 phosphorylation in incubated
mouse muscle. A: 2DG uptake in incubated soleus and EDL at basal conditions and after incubation with 100 ng/ml CNTF at indicated periods of
time. B: Akt S473 phosphorylation in lysates from incubated soleus and EDL at basal conditions and after incubation with 100 ng/ml CNTF at
indicated periods of time. C: AMPK T172 phosphorylation in lysates from incubated soleus and EDL at basal conditions and after incubation with
100 ng/ml CNTF. D: ACC S218 phosphorylation in lysates from incubated soleus and EDL at basal conditions and after incubation with 100 ng/ml
CNTF. n  8. Data are means  SEM. *Signiﬁcantly different from basal condition.
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FIG. 4. Effect of impaired AMPK signaling and the PI3-kinase inhibitor LY-294002 on CNTF-stimulated 2-deoxyglucose (2DG) uptake, AMPK
activity, and Akt S473 and STAT3 Y705 phosphorylation in incubated mouse muscle from wild-type (WT) and AMPK KD (Tg) mice. A: 2DG uptake
at basal and after incubation with 100 ng/ml CNTF with or without 60 nmol/l of LY-294002 in soleus (left panel) and EDL (right panel) muscle.
In addition, incubation of wild-type muscle at basal with 2.8 nmol/l insulin (ins) with and without LY-294002. B: -Isoform–speciﬁc AMPK activity
in lysates from incubated soleus (left panel) and EDL (right panel) muscle at basal and after incubation with 100 ng/ml CNTF for 30 min. C:
STAT3 Y705 phosphorylation in lysates from incubated EDL muscle at basal and after incubation with 100 ng/ml CNTF with and without
LY-294002. D: Akt phosphorylation in lysates from incubated EDL at basal and after incubation with 100 ng/ml CNTF with and without LY-294002.
n  8. Data are means  SEM. *Signiﬁcantly different from basal condition. †Signiﬁcantly different from CNTF or insulin stimulated. Signiﬁcantly
different from WT.
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muscle in vitro through the PI3-kinase/Akt signaling path-
way. It was expected that AMPK would also exert a role in
this process, but we found that AMPK was not required for
CNTF to stimulate glucose uptake. Skeletal muscle is the
most important tissue for insulin-stimulated glucose dis-
posal (44), and skeletal muscle insulin resistance is a
major defect in most obese phenotypes. Accordingly, we
investigated whether CNTF-stimulated glucose uptake
was maintained in muscle from obese, insulin-resistant
mice. The rationale for these studies was to establish
whether gp130-LIF signaling could constitute an alterna-
tive pathway to substitute for insufﬁcient insulin signaling
to skeletal muscle glucose uptake. However, obesity was
associated with impaired CNTF-stimulated glucose up-
take, which, at least in part, may have been attributed to
increased muscle lipids and impaired PI3-kinase/Akt sig-
naling with CNTF.
CNTF is a peptide hormone of the IL-6 family, which is
highly expressed in peripheral nerves and other tissues
(24,45,46). CNTF levels are low in serum of healthy
individual as a result of the absence of an exocytosis
targeting sequence (47,48). Recent reports have shown
signiﬁcant promise for the use of CNTF as an antiobesity
therapeutic because it suppresses food intake acutely (49)
and induces hypothalamic neurogenesis (50), leading to a
new set point in body mass. CNTF also has direct antidi-
abetic effects in peripheral tissues. Chronic treatment of
obese diabetic mice with CNTF increases metabolic rate
(51) and reduces liver steatosis by enhancing fat oxidation
and reducing synthesis of complex lipids (52). We have
recently shown that chronic CNTF treatment of obese
diabetic mice reverses obesity-induced insulin resistance
by activating AMPK and reducing muscle lipid accumula-
tion (20). In line with this study, CNTF acutely prevents
muscle insulin resistance in response to a 2-h lipid infusion
by preventing lipid accumulation (27). The clinical efﬁcacy
and safety of CNTF as a possible therapeutic for obesity is
supported by ﬁndings in humans demonstrating weight
loss and improved glycemic control (53).
Because we previously showed that CNTF activates
AMPK in muscle (20) and AMPK is well known to increase
glucose uptake in skeletal muscle (15,54,55), we expected
AMPK rather than PI3-kinase/Akt signaling to be required
for CNTF-stimulated glucose uptake. However, multiple
lines of evidence indicate that CNTF signaling to glucose
uptake may be mediated by a PI3-kinase/Akt–dependent
signaling pathway: 1) the kinetics in Akt S473 phosphory-
lation correlated with increases in glucose uptake in both
soleus and EDL muscles; 2) incubation with the PI3-kinase
inhibitor, LY-294002, completely blocked CNTF-stimulated
Akt phosphorylation and glucose uptake; 3) CNTF in-
creased glucose uptake was not impaired in muscles
overexpressing a KD AMPK2; 4) AMPK was not activated
by CNTF in the EDL muscle despite a 100% increase in
glucose uptake; 5) a knockin mutation of a truncated
gp130 receptor, which impairs gp130 signaling toward
STAT3 and AMPK, had no effect on CNTF-stimulated
glucose uptake; and 6) obesity induced by an HFD or
treatment of cells with C2-ceramide impaired CNTF stim-
ulated glucose uptake and was associated with blunted
Akt but not AMPK phosphorylation. However, our ﬁndings
demonstrating that CNTF-stimulated glucose uptake was
additive to a maximal dose of insulin in Soleus, but not
EDL muscle suggest that under some conditions, AMPK
activation may also play a role in the stimulation of
glucose uptake in Soleus, albeit to a lesser extent than
originally anticipated. A possible explanation for the lim-
ited role of AMPK in CNTF-stimulated glucose uptake is
that CNTF predominantly activated the 1-AMPK isoform.
Studies in AMPK2-null mice have shown that AMPK2,
but not 1 is required for the regulation of muscle glucose
uptake in response to stimuli such as AICAR (15), possibly
explaining why CNTF activation of AMPK is not required
to increase glucose transport.
Because we found CNTF to increase muscle glucose
uptake, it was of interest to test the effects of CNTF in
insulin-resistant muscle from obese mice. We found that
the efﬁcacy of CNTF to regulate glucose uptake was
reduced by 
50% or more in muscles from obese HFD-fed
and ob/ob mice. CNTF resistance with obesity seems not to
be the result of impaired activation of the gp130-LIF
receptor complex because CNTF-induced phosphorylation
of AMPK and STAT3 were normal in obese muscle. In
contrast, CNTF-stimulated phosphorylation of Akt was
suppressed in obese muscles and was associated with
muscle DAG and ceramide accumulation. Ceramides
downregulate Akt phosphorylation and membrane trans-
location by activating protein phosphatase 2A (56). Cer-
amides also increase the activity of protein kinase C ,
leading to inhibitory Akt S34 phosphorylation (57). In
addition to the ﬁnding that ceramides were elevated in
muscle from obese mice, our studies in myotubes showed
that the C2-ceramide not only reduced basal Akt phos-
phorylation but also completely prevented CNTF-induced
•
•
FIG. 5. CNTF-induced 2-deoxyglucose (2DG) uptake (A) and STAT3
Y705 and Akt S473 phosphorylation (B) in incubated soleus and EDL
mouse muscle from wild-type (WT) and gp130
STAT mice. (Muscles
were either incubated at basal condition or with 100 ng/ml CNTF for 30
min [n  8].) Data are means  SEM. *Signiﬁcantly different from basal
condition.
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take. These results agree with previous studies in myo-
tubes (33) and isolated rodent (32) and human (58)
skeletal muscle demonstrating impaired insulin-stimulated
Akt activation and glucose uptake when ceramides are
elevated. In the present studies, DAG and a reduction in
PI-3 kinase activity may have also contributed to the
reduced CNTF activation of Akt in muscles from obese
animals. Importantly, the ﬁnding that neither the C2-
ceramide nor obesity altered CNTF-induced STAT3 and
AMPK phosphorylation is consistent with our previous
ﬁndings that CNTF activation of AMPK and lipid metabo-
lism is maintained in skeletal muscles from obese, insulin-
resistant mouse models (20). Thus, although the signaling
arm of CNTF to glucose uptake is compromised with
obesity, the activation of AMPK and lipid oxidation is
preserved.
In summary, our data show that CNTF-stimulated glu-
cose uptake is associated with activation of the PI3-kinase/
Akt signaling pathway. Furthermore, CNTF-stimulated Akt
•
•
•
•
FIG. 6. CNTF-stimulated 2-deoxyglucose (2DG) uptake in high-fat
diet–fed (A) and ob/ob mice (B), STAT3 Y705 (C), Akt S473 (D), and
AMPK T172 (E) phosphorylation in soleus and EDL mouse muscle from
mice fed standard chow (Ch) or an HFD for 12 weeks; n  8–10 for HFD
experiment and 7–8 for ob/ob experiment. Data are means  SEM.
*Signiﬁcantly different from basal condition (P < 0.05, P < 0.001).
†Signiﬁcantly different from CNTF-stimulated chow-fed/control mice.
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FIG. 7. Muscle lipids in gastrocnemius muscle from mice fed standard chow or an HFD and STAT3 Y705, Akt S473, and AMPK T172
phosphorylation in C2C12 myocytes. A: Muscle content of triacylglycerol (TAG), diacylglycerol (DAG), and ceramides. B: CNTF and
insulin-stimulated 2-deoxy-D-glucose uptake in L6 myotubes treated with either C2-ceramide or vehicle for 6 h. C–E: Phosphorylation of
CNTF-activated signaling molecules in C2C12 myotubes treated with C2-ceramide for6ho rCNTF for 30 min or in combination. *Signiﬁcantly
different from basal condition (P < 0.05, P < 0.001).
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muscles from obese insulin-resistant mice despite the
maintenance of STAT3 and AMPK signaling. This mecha-
nism may, in part, be attributable to ceramide accumula-
tion with obesity, which in turn impairs CNTF signaling to
the PI3-kinase/Akt signaling arm of the gp130 receptor.
Because CNTF-induced activation of AMPK was main-
tained in obesity, CNTF or CNTF analogs provide the
bases for a viable therapeutic to prevent muscle lipid
accumulation and to restore insulin sensitivity in obesity.
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